Dr. Davids is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-3000Fax+1 617-632-5822
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2011
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2005 - 2008
- Yale School of MedicineClass of 2005
Certifications & Licensure
- MA State Medical License 2008 - 2026
- CT State Medical License 2022 - 2025
- NY State Medical License 2007 - 2009
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Young Scientist Award Lymphoma Foundation of America, 2012
Clinical Trials
- Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Start of enrollment: 2013 May 16
- A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL Start of enrollment: 2014 Jun 27
- A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2014 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 257 citationsSmall molecules, big impact: 20 years of targeted therapy in oncology.Philippe L. Bedard, David M. Hyman, Matthew S. Davids, Lillian L. Siu
Lancet. 2020-03-28 - 262 citationsPI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.Antonino Glaviano, Aaron S C Foo, Hiu Y Lam, Kenneth C H Yap, William Jacot
Molecular Cancer. 2023-08-18 - 78 citationsConsensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.Philipp B. Staber, Marco Herling, Mar Bellido, Eric D. Jacobsen, Matthew S. Davids
Blood. 2019-10-03
Journal Articles
- The Phase 3 DUO Trial: Duvelisib Versus Ofatumumab in Relapsed and Refractory CLL/SLLMatthew S Davids, Ian W Flinn, Craig A Portell, Nicole Lamanna, Scott Lunin, Amanda F Cashen, Blood
Abstracts/Posters
- Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Early Adoption and Outcomes of Ibrutinib As Treatment for Older Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based StudyMatthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Other
- The Rise of Apoptosis: Targeting Apoptosis in Hematologic MalignanciesMatthew Davids, MD, Blood
https://www.doximity.com/articles/98c8dcba-e43a-4f7a-a7f7-4f3bd29ea5d9
UpToDate, Wolters Kluwer Health - 2013-03-29
Press Mentions
- ASH 2024 | Results from Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report USA - English APAC - Traditional ChineseNovember 6th, 2024
- Mapping Genetic Evolution from CLL to Richter’s SyndromeJanuary 10th, 2023
- ASH 2022: New Findings in CLLDecember 28th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: